{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.899","value":"-97.469"},{"groupId":"OG001","spread":"145.247","value":"39.293"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"42"}],"units":"Participants"}],"title":"Week 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.235","value":"-98.777"},{"groupId":"OG001","spread":"78.469","value":"-5.186"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"36"}],"units":"Participants"}],"title":"Week 4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.506","value":"-97.045"},{"groupId":"OG001","spread":"134.421","value":"0.661"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"45"}],"units":"Participants"}],"title":"Week 12"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.207","value":"-96.628"},{"groupId":"OG001","spread":"86.793","value":"-11.446"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"37"}],"units":"Participants"}],"title":"Week 24"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.677","value":"-98.620"},{"groupId":"OG001","spread":"220.857","value":"37.695"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"42"}],"units":"Participants"}],"title":"Week 52"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"380.111","value":"77.123"},{"groupId":"OG001","spread":"31.519","value":"-76.055"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"title":"Week 104"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"402.281","value":"105.043"},{"groupId":"OG001","spread":"19.755","value":"-73.889"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"title":"Bcfu Month 6"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"380.111","value":"77.123"},{"groupId":"OG001","spread":"31.519","value":"-76.055"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"title":"Bcfu Month 12"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.701","value":"-83.159"},{"comment":"The standard deviation could not be derived from the data of 1 participant.","groupId":"OG001","spread":"NA","value":"-11.418"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Bcfu Month 18"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.836","value":"-93.603"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Bcfu Month 24"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"50.807","value":"-59.950"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Bcfu Month 30"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.973","value":"-99.163"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Bcfu Month 36"},{"categories":[{"measurements":[{"comment":"The standard deviation could not be derived from the data of 1 participant.","groupId":"OG000","spread":"NA","value":"-99.084"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Bcfu Month 42"},{"categories":[{"measurements":[{"comment":"The standard deviation could not be derived from the data of 1 participant.","groupId":"OG000","spread":"NA","value":"-99.851"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Bcfu Month 48"}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"62"}],"units":"Participants"}],"description":"CD19+ B cell is a B-lymphocyte with a transmembrane protein that is encoded by the gene CD19.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received obinutuzumab 1000 milligrams (mg) intravenous (IV) infusion on Days 1, 15, 168, and 182 along with MMF/MPA at a starting dose of 1500 mg/day (or equivalent) administered orally in 2 or 3 divided doses. MMF/MPA dose was up titrated to a target dose of 2.0 - 2.5 grams per day (g/day) (or equivalent). Investigators, at their discretion, could use MPA as a substitute for MMF, with a 360 mg dose being equivalent to a 500 mg dose of MMF. During screening or at randomization, if clinically indicated, participants could receive 1000 mg methylprednisolone IV once daily for up to 3 days to treat underlying LN clinical activity. Participants received 0.5 mg/kg oral prednisone, tapering this prednisone dose, per protocol, starting on Day 16 and reducing the prednisone dosage to 7.5 mg/day by Week 12.","id":"OG000","title":"OBINUTUZUMAB 1000MG and MMF"},{"description":"Participants received placebo matching to obinutuzumab IV infusion on Days 1, 15, 168, and 182 along with MMF/MPA at a starting dose of 1500 mg/day (or equivalent) administered orally in 2 or 3 divided doses. MMF/MPA dose was up titrated to a target dose of 2.0 - 2.5 g/day (or equivalent). Investigators, at their discretion, could use MPA as a substitute for MMF, with a 360 mg dose being equivalent to a 500 mg dose of MMF. During screening or at randomization, if clinically indicated, participants could receive 1000 mg methylprednisolone IV once daily for up to 3 days to treat underlying LN clinical activity. Participants received 0.5 mg/kg oral prednisone, tapering this prednisone dose, per protocol, starting on Day 16 and reducing the prednisone dosage to 7.5 mg/day by Week 12.","id":"OG001","title":"PLACEBO and MMF"}],"paramType":"MEAN","populationDescription":"Modified intent-to-treat population will include all randomized participants who have received any amount of study drug. Participants who received an incorrect therapy were reported under the treatment arm to which they were randomized.","reportingStatus":"POSTED","timeFrame":"Baseline, Week 2, Week 4, Week 12, Week 24, Week 52, Week 104, B Cell Follow-Up (Bcfu) at months 6, 12, 18, 24, 30, 36, 42 and 48","title":"Percent Change From Baseline in Circulating CD19-Positive B-Cell Levels","type":"SECONDARY","unitOfMeasure":"Percent change of cells/uL"}